Evidence map›Paper›PMID 41254308›Full record

ArticlePulmonary therapy2026

Double-Blind Randomized Placebo-Controlled Trial of a Lactobacillus Probiotic Blend in Chronic Obstructive Pulmonary Disease.

Teodora Nicola, Nancy M Wenger, Kara Seidman, Michael Evans, Youfeng Yang, Dongquan Chen, William J Van Der Pol, Amar Walia, Elliot J Lefkowitz, Jun Wang and 6 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pulmonary therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05523180 (A Prospective, Randomized, Double-blinded, Placebo-controlled Study Evaluating the Safety and Impact of resB® Lung Support on Quality of Life in Adult Volunteers With Chronic Obstructive Pulmonary Disease or Non-cystic Fibrosis Bronchiectasis), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05523180 nacompletednot on this map

A Prospective, Randomized, Double-blinded, Placebo-controlled Study Evaluating the Safety and Impact of resB® Lung Support on Quality of Life in Adult Volunteers With Chronic Obstructive Pulmonary Disease or Non-cystic Fibrosis Bronchiectasis

TypeinterventionalSponsorResBiotic Nutrition, Inc.Ran2022 to 2023Enrolled37ConditionsChronic Obstructive Pulmonary Disease, Non-cystic Fibrosis BronchiectasisArmsProbiotic, Placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Teodora NicolaDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
Nancy M WengerDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
Kara SeidmanDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
Michael EvansDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
Youfeng YangDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
Dongquan ChenDepartment of Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
William J Van Der PolCenter for Clinical and Translational Science, University of Alabama at Birmingham, Birmingham, AL, USA.
Amar WaliaDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
Elliot J LefkowitzDepartment of Microbiology, University of Alabama at Birmingham, Birmingham, AL, USA.
Jun WangNutrasource Pharmaceutical and Nutraceutical Services, Inc., Guelph, ON, Canada.
Ashley LeMoireNutrasource Pharmaceutical and Nutraceutical Services, Inc., Guelph, ON, Canada.
Lois LinNutrasource Pharmaceutical and Nutraceutical Services, Inc., Guelph, ON, Canada.
Casey MorrowDepartment of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA.
Namasivayam AmbalavananDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
Amit GaggarDivision of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Charitharth Vivek LalDepartment of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA. clal@uabmc.edu.

Funding

CTSA UM1 at the University of Alabama at BirminghamUM1TR004771 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI PATRICE DELAFONTAINE, Orlando M Gutierrez · 2024 to 2026
$29.2M
An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPDR44HL164156 · NHLBI · RESBIOTIC, INC. · PI NICOLA, TEODORA · 2023 to 2025
$2.3M
Mechanisms of Pulmonary Microbiota-Induced Inflammation and Vascular Dysfunction in Neonatal Lung InjuryK08HL141652 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LAL, CHARITHARTH VIVEK · 2019 to 2023
$838k
NCATS NIH HHS UM1TR004771NHLBI NIH HHS K08 HL141652NHLBI NIH HHS R44HL164156
6 · The paper itself

Abstract

introductionGut microbiota modulate systemic anti-inflammatory and immune responses in the lungs, suggesting a potential to support lung health through probiotic supplementation. We hypothesized that a probiotic blend (Lactobacilli) combined with herbal extracts (resB

methodsWe conducted a randomized, double-blinded, placebo-controlled study (NCT05523180) evaluating the safety and impact of resB

resultsParticipants receiving resB

conclusionThese findings suggest that resB

trial registrationClinicalTrials.gov identifier NCT05523180.

Indexed as

Chronic obstructive pulmonary diseaseClinical trialGut–lung axisInflammationMicrobiomeProbiotics

Identifiers

PMID41254308
PMCPMC12992734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.